B cells and progressive multifocal leukoencephalopathy: Search for the missing link

Frontiers in Immunology

Volumn 6, Issue MAY, 2015, Pages

  Durali, Deniz ^a   De Goër De Herve, Marie Ghislaine ^b   Gasnault, Jacques ^b   Taoufik, Yassine ^b  

^a ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^b INSERM U1184   (France)

Author keywords

B cells; Immune regulation; JC virus; Progressive multifocal leukoencephalopathy; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 35; INTERLEUKIN 4; LYMPHOTOXIN; NATALIZUMAB; NUCLEAR FACTOR 1 X TYPE; NUCLEIC ACID BINDING PROTEIN; RITUXIMAB; TRANSCRIPTION FACTOR SPI B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; INFECTION CONTROL; JC VIRUS; NONHUMAN; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; SECRETION (PROCESS); SHORT SURVEY; VIRUS CARRIER; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84934298613     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00241     Document Type: Short Survey

References (130)

1. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol (2009) 10:816-24. doi: 10.1016/S1470-2045(09)70161-5
2. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol (2010) 9:425-37. doi:10.1016/S1474-4422(10)70040-5
3. Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One (2011) 6:e20967. doi:10.1371/journal.pone.0020967
4. Gasnault J, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF, Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS (2003) 17:1443-9. doi:10.1097/00002030-200307040-00004
5. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis (2009) 199:77-83. doi:10.1086/595299
6. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood (2009) 113:4834-40. doi:10.1182/blood-2008-10-186999
7. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol (2011) 68:1156-64. doi:10.1001/archneurol.2011.103
8. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy-revisited. J Infect Dis (2011) 203:578-86. doi:10.1093/infdis/jiq097
9. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol (2000) 6:127-36. doi:10.3109/13550280009013156
10. Major EO, Amemiya K, Elder G, Houff SA. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res (1990) 27:461-71. doi:10.1002/jnr.490270405
11. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (1992) 5:49-73.
12. Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis (2010) 202:184-91. doi:10.1086/653823
13. Monaco MC, Shin J, Major EO. JC virus infection in cells from lymphoid tissue. Dev Biol Stand (1998) 94:115-22.
14. Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med (1988) 318:301-5. doi:10.1056/NEJM198802043180507
15. Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol (1996) 70:7004-12.
16. Monaco MC, Jensen PN, Hou J, Durham LC, Major EO. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol (1998) 72:9918-23.
17. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med (2010) 61:35-47. doi:10.1146/annurev.med.080708.082655
18. Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller C, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis (2009) 199:881-8. doi:10.1086/597117
19. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 6:667-79. doi:10.1038/nrneurol.2010.164
20. Yogo Y, Kitamura T, Sugimoto C, Ueki T, Aso Y, Hara K, et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol (1990) 64:3139-43.
21. Pietropaolo V, Videtta M, Fioriti D, Mischitelli M, Arancio A, Orsi N, et al. Rearrangement patterns of JC virus noncoding control region from different biological samples. J Neurovirol (2003) 9:603-11. doi:10.1080/jnv.9.6.603.611
22. Han GP, Miura K, Ide Y, Tsutsui Y. Genetic analysis of JC virus and BK virus from a patient with progressive multifocal leukoencephalopathy with hyper IgM syndrome. J Med Virol (2005) 76:398-405. doi:10.1002/jmv.20377
23. Marzocchetti A, Wuthrich C, Tan CS, Tompkins T, Bernal-Cano F, Bhargava P, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol (2008) 14:455-8. doi:10.1080/13550280802356837
24. Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis (2011) 204:237-44. doi:10.1093/infdis/jir256
25. Marshall LJ, Ferenczy MW, Daley EL, Jensen PN, Ryschkewitsch CF, Major EO. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol (2014) 88:5177-83. doi:10.1128/JVI.03221-13
26. Bellizzi A, Nardis C, Anzivino E, Rodio D, Fioriti D, Mischitelli M, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol (2012) 18:1-11. doi:10.1007/s13365-012-0080-7
27. Marshall LJ, Major EO. Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy. J Neuroimmune Pharmacol (2010) 5:404-17. doi:10.1007/s11481-010-9203-1
28. Atwood WJ, Amemiya K, Traub R, Harms J, Major EO. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology (1992) 190:716-23. doi:10.1016/0042-6822(92)90909-9
29. Rieckmann P, Michel U, Kehrl JH. Regulation of JC virus expression in B lymphocytes. J Virol (1994) 68:217-22.
30. Miyamura T, Furuno A, Yoshiike K. DNA rearrangement in the control region for early transcription in a human polyomavirus JC host range mutant capable of growing in human embryonic kidney cells. J Virol (1985) 54:750-6.
31. Vaz B, Cinque P, Pickhardt M, Weber T. Analysis of the transcriptional control region in progressive multifocal leukoencephalopathy. J Neurovirol (2000) 6:398-409. doi:10.3109/13550280009018304
32. Gosert R, Kardas P, Major EO, Hirsch HH. Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol (2010) 84:10448-56. doi:10.1128/JVI.00614-10
33. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 25:471-506. doi:10.1128/CMR.05031-11
34. Monaco MC, Sabath BF, Durham LC, Major EO. JC virus multiplication in human hematopoietic progenitor cells requires the NF-1 class D transcription factor. J Virol (2001) 75:9687-95. doi:10.1128/JVI.75.20.9687-9695.2001
35. Marshall LJ, Dunham L, Major EO. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity. J Gen Virol (2010) 91:3042-52. doi:10.1099/vir.0.023184-0
36. Marshall LJ, Moore LD, Mirsky MM, Major EO. JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes. J Gen Virol (2012) 93:651-61. doi:10.1099/vir.0.035832-0
37. Ault GS, Stoner GL. Human polyomavirus JC promoter/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure. J Gen Virol (1993) 74(Pt 8):1499-507. doi:10.1099/0022-1317-74-8-1499
38. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) (2007) 46:29-36. doi:10.1093/rheumatology/kel148
39. Roll P, Dörner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum (2008) 58:1566-75. doi:10.1002/art.23473
40. Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol (2007) 122:139-45. doi:10.1016/j.clim.2006.08.009
41. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol (2009) 182:5982-93. doi:10.4049/jimmunol.0801859
42. Abulayha AM, Tabal SA, Shawesh EI, Elbasir MA, Elbanani AS, Lamami YM, et al. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma. Leuk Res (2010) 34:307-11. doi:10.1016/j.leukres.2009.06.005
43. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology (2008) 71:1350-4. doi:10.1212/01.wnl.0000327671.91357.96
44. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity (2007) 27:384-92. doi:10.1016/j.immuni.2007.09.002
45. Sindic CJ, Trebst C, Van Antwerpen MP, Frye S, Enzensberger W, Hunsmann G, et al. Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. J Neuroimmunol (1997) 76:100-4. doi:10.1016/S0165-5728(97)00037-4
46. Denne C, Kleines M, Dieckhofer A, Ritter K, Scheithauer S, Merz U, et al. Intrathecal synthesis of anti-viral antibodies in pediatric patients. Eur J Paediatr Neurol (2007) 11:29-34. doi:10.1016/j.ejpn.2006.10.003
47. Robinson-Agramonte M, Reiber H, Cabrera-Gomez JA, Galvizu R. Intrathecalpolyspecific immune response to neurotropic viruses in multiple sclerosis: a comparative report from Cuban patients. Acta Neurol Scand (2007) 115:312-8. doi:10.1111/j.1600-0404.2006.00755.x
48. Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, Castro MJ, Faria LC, Peralta JM. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology (2009) 73:1413-7. doi:10.1212/WNL.0b013e3181bd8258
49. Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis (1997) 176:250-4. doi:10.1086/514032
50. Vandvik B, Nilsen RE, Vartdal F, Norrby E. Mumps meningitis: specific and non-specific antibody responses in the central nervous system. Acta Neurol Scand (1982) 65:468-87. doi:10.1111/j.1600-0404.1982.tb03104.x
51. Luxton RW, Thompson EJ. Affinity distributions of antigen-specific IgG in patients with multiple sclerosis and in patients with viral encephalitis. J Immunol Methods (1990) 131:277-82. doi:10.1016/0022-1759(90)90199-6
52. Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig (1992) 70:28-37. doi:10.1007/BF00422934
53. Sindic CJ, Monteyne P, Laterre EC. The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. J Neuroimmunol (1994) 54:75-80. doi:10.1016/0165-5728(94)90233-X
54. Luxton RW, Zeman A, Holzel H, Harvey P, Wilson J, Kocen R, et al. Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis. J Neurol Sci (1995) 132:11-9. doi:10.1016/0022-510X(95)00115-I
55. Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol (2009) 83:4404-11. doi:10.1128/JVI.02657-08
56. Weber F, Goldmann C, Kramer M, Kaup FJ, Pickhardt M, Young P, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol (2001) 49:636-42. doi:10.1002/ana.1004.abs
57. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol (2006) 180:63-70. doi:10.1016/j.jneuroim.2006.06.029
58. Reis EA, Athanazio DA, Lima I, Oliveira e Silva N, Andrade JC, Jesus RN, et al. NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int (2009) 29:469-75. doi:10.1007/s00296-008-0719-0
59. Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) (2008) 47:821-7. doi:10.1093/rheumatology/ken071
60. Stasi R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin Hematol (2010) 47:170-9. doi:10.1053/j.seminhematol.2010.01.010
61. Melet J, Mulleman D, Goupille P, Ribourtout B, Watier H, Thibault G. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum (2013) 65:2783-90. doi:10.1002/art.38107
62. Lykken JM, DiLillo DJ, Weimer ET, Roser-Page S, Heise MT, Grayson JM, et al. Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice. J Immunol (2014) 193:746-56. doi:10.4049/jimmunol.1302848
63. Hunziker L, Klenerman P, Zinkernagel RM, Ehl S. Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells. Eur J Immunol (2002) 32:374-82. doi:10.1002/1521-4141(200202)32:2 <374::AID-IMMU374> 3.0.CO;2-9
64. Brundler MA, Aichele P, Bachmann M, Kitamura D, Rajewsky K, Zinkernagel RM, et al. Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory. Eur J Immunol (1996) 26:2257-62. doi:10.1002/eji.1830260943
65. Asano MS, Ahmed R. CD8 T cell memory in B cell-deficient mice. J Exp Med (1996) 183:2165-74. doi:10.1084/jem.183.5.2165
66. Topham DJ, Tripp RA, Hamilton-Easton AM, Sarawar SR, Doherty PC. Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig. J Immunol (1996) 157:2947-52.
67. Thomsen AR, Johansen J, Marker O, Christensen JP. Exhaustion of CTL memory and recrudescence of viremia in lymphocytic choriomeningitis virus-infected MHC class II-deficient mice and B cell-deficient mice. J Immunol (1996) 157:3074-80.
68. Whitmire JK, Asano MS, Kaech SM, Sarkar S, Hannum LG, Shlomchik MJ, et al. Requirement of B cells for generating CD4+ T cell memory. J Immunol (2009) 182:1868-76. doi:10.4049/jimmunol.0802501
69. Shen H, Whitmire JK, Fan X, Shedlock DJ, Kaech SM, Ahmed R. A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes. J Immunol (2003) 170:1443-51. doi:10.4049/jimmunol.170.3.1443
70. Rocha B, Tanchot C. Towards a cellular definition of CD8+ T-cell memory: the role of CD4+ T-cell help in CD8+ T-cell responses. Curr Opin Immunol (2004) 16:259-63. doi:10.1016/j.coi.2004.03.004
71. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 5:927-33. doi:10.1038/ni1105
72. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol (2007) 25:171-92. doi:10.1146/annurev.immunol.25.022106.141548
73. de Goer de Herve MG, Cariou A, Simonetta F, Taoufik Y. Heterospecific CD4 help to rescue CD8 T cell killers. J Immunol (2008) 181:5974-80. doi:10.4049/jimmunol.181.9.5974
74. de Goer de Herve MG, Dembele B, Vallee M, Herr F, Cariou A, Taoufik Y. Direct CD4 help provision following interaction of memory CD4 and CD8 T cells with distinct antigen-presenting dendritic cells. J Immunol (2010) 185:1028-36. doi:10.4049/jimmunol.0904209
75. de Goer de Herve MG, Jaafoura S, Vallee M, Taoufik Y. FoxP3(+) regulatory CD4 T cells control the generation of functional CD8 memory. Nat Commun (2012) 3:986. doi:10.1038/ncomms1992
76. Homann D, Tishon A, Berger DP, Weigle WO, von Herrath MG, Oldstone MB. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J Virol (1998) 72:9208-16.
77. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, et al. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 104:20878-83. doi:10.1073/pnas.0709205105
78. Mollo SB, Zajac AJ, Harrington LE. Temporal requirements for B cells in the establishment of CD4 T cell memory. J Immunol (2013) 191:6052-9. doi:10.4049/jimmunol.1302033
79. Misumi I, Whitmire JK. B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J Immunol (2014) 192:1597-608. doi:10.4049/jimmunol.1302661
80. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol (2008) 20:332-8. doi:10.1016/j.coi.2008.03.003
81. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 10:236-47. doi:10.1038/nri2729
82. DiLillo DJ, Horikawa M, Tedder TF. B-lymphocyte effector functions in health and disease. Immunol Res (2011) 49:281-92. doi:10.1007/s12026-010-8189-3
83. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 224:201-14. doi:10.1111/j.1600-065X.2008.00661.x
84. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol (2006) 176:705-10. doi:10.4049/jimmunol.176.2.705
85. Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today (1997) 18:343-50. doi:10.1016/S0167-5699(97)01080-3
86. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol (2000) 1:475-82. doi:10.1038/82717
87. Harris DP, Goodrich S, Gerth AJ, Peng SL, Lund FE. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol (2005) 174:6781-90. doi:10.4049/jimmunol.174.11.6781
88. Harris DP, Goodrich S, Mohrs K, Mohrs M, Lund FE. Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol (2005) 175:7103-7. doi:10.4049/jimmunol.175.11.7103
89. Durali D, de Goer de Herve MG, Giron-Michel J, Azzarone B, Delfraissy JF, Taoufik Y. In human B cells, IL-12 triggers a cascade of molecular events similar to Th1 commitment. Blood (2003) 102:4084-9. doi:10.1182/blood-2003-02-0518
90. de Goer de Herve MG, Durali D, Dembele B, Giuliani M, Tran TA, Azzarone B, et al. Interferon-alpha triggers B cell effector 1 (Be1) commitment. PLoS One (2011) 6:e19366. doi:10.1371/journal.pone.0019366
91. Scandella E, Fink K, Junt T, Senn BM, Lattmann E, Förster R, et al. Dendritic cell-independent B cell activation during acute virus infection: a role for early CCR7-driven B-T helper cell collaboration. J Immunol (2007) 178:1468-76. doi:10.4049/jimmunol.178.3.1468
92. Wu J, Qin D, Burton GF, Szakal AK, Tew JG. Follicular dendritic cell-derived antigen and accessory activity in initiation of memory IgG responses in vitro. J Immunol (1996) 157:3404-11.
93. Tew JG, Wu J, Qin D, Helm S, Burton GF, Szakal AK. Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol Rev (1997) 156:39-52. doi:10.1111/j.1600-065X.1997.tb00957.x
94. Dustin ML, Dustin LB. The immunological relay race: B cells take antigen by synapse. Nat Immunol (2001) 2:480-2. doi:10.1038/88666
95. Weber T, Weber F, Petry H, Luke W. Immune response in progressive multifocal leukoencephalopathy: an overview. J Neurovirol (2001) 7:311-7. doi:10.1080/13550280152537166
96. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology (2011) 77:1061-7. doi:10.1212/WNL.0b013e31822e55e7
97. Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology (2012) 78:1390-3. doi:10.1212/WNL.0b013e318253d61e
98. Aly L, Yousef S, Schippling S, Jelcic I, Breiden P, Matschke J, et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 134:2687-702. doi:10.1093/brain/awr206
99. Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood (2006) 107:806-12. doi:10.1182/blood-2005-01-0154
100. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 67:452-61. doi:10.1002/ana.21939
101. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol (2002) 3:944-50. doi:10.1038/ni833
102. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity (2010) 32:129-40. doi:10.1016/j.immuni.2009.11.009
103. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol (2007) 178:3447-56. doi:10.4049/jimmunol.178.6.3447
104. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol (2011) 186:5569-79. doi:10.4049/jimmunol.1100284
105. Hilgenberg E, Shen P, Dang VD, Ries S, Sakwa I, Fillatreau S. Interleukin-10-producing B cells and the regulation of immunity. Curr Top Microbiol Immunol (2014) 380:69-92. doi:10.1007/978-3-662-43492-5_4
106. Woodle ES, Rothstein DM. Clinical implications of basic science discoveries: Janus resurrected-two faces of B cell and plasma cell biology. Am J Transplant (2015) 15:39-43. doi:10.1111/ajt.13028
107. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol (2007) 123:66-73. doi:10.1016/j.clim.2006.12.006
108. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2007) 122:62-74. doi:10.1016/j.clim.2006.08.016
109. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther (2006) 8:R83. doi:10.1186/ar1954
110. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood (2008) 111:5334-41. doi:10.1182/blood-2007-11-122713
111. Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood (2008) 112:1147-50. doi:10.1182/blood-2007-12-129262
112. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum (2006) 54:2377-86. doi:10.1002/art.22019
113. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol (2007) 178:6092-9. doi:10.4049/jimmunol.178.10.6092
114. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 54:613-20. doi:10.1002/art.21617
115. Sun F, Ladha SS, Yang L, Liu Q, Shi SX, Su N, et al. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis. Muscle Nerve (2014) 49:487-94. doi:10.1002/mus.23951
116. Catzola V, Battaglia A, Buzzonetti A, Fossati M, Scuderi F, Fattorossi A, et al. Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis. J Neurol (2013) 260:2163-5. doi:10.1007/s00415-013-6987-y
117. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med (2013) 5:173ra123. doi:10.1126/scitranslmed.3005407
118. Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity (2014) 41:1040-51. doi:10.1016/j.immuni.2014.10.016
119. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature (2014) 507:366-70. doi:10.1038/nature12979
120. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 450:566-9. doi:10.1038/nature06306
121. Tedder TF, Leonard WJ. Autoimmunity: regulatory B cells-IL-35 and IL-21 regulate the regulators. Nat Rev Rheumatol (2014) 10:452-3. doi:10.1038/nrrheum.2014.95
122. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med (2014) 20:633-41. doi:10.1038/nm.3554
123. Stuve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol (2005) 62:1620-3. doi:10.1001/archneur.62.10.1620
124. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol (2012) 142:31-7. doi:10.1016/j.clim.2011.04.005
125. Petereit HF, Rubbert A. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch Neurol (2005) 62:1641-2. doi:10.1001/archneur.62.10.1641-b
126. Stuve O, Leussink VI, Frohlich R, Hemmer B, Hartung HP, Menge T, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol (2009) 66:259-61. doi:10.1001/archneurol.2008.551
127. Martin Mdel P, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol (2009) 66:1016-20. doi:10.1001/archneurol.2009.157
128. Mutnal MB, Hu S, Schachtele SJ, Lokensgard JR. Infiltrating regulatory B cells control neuroinflammation following viral brain infection. J Immunol (2014) 193:6070-80. doi:10.4049/jimmunol.1400654
129. Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci (2011) 31:8556-63. doi:10.1523/JNEUROSCI.1623-11.2011
130. Chen D, Blazek M, Ireland S, Ortega S, Kong X, Meeuwissen A, et al. Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms. J Immunol (2014) 193:4823-32. doi:10.4049/jimmunol.1401478